Conor MacKay
Stock Analyst at BMO Capital
(0.73)
# 4,164
Out of 5,096 analysts
11
Total ratings
37.5%
Success rate
-11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Conor MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterated: Buy | $192 | $112.58 | +70.55% | 6 | Oct 30, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $36 | $13.56 | +165.49% | 2 | Oct 6, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $58 | $20.06 | +189.13% | 3 | Sep 21, 2026 |
Insmed
Oct 30, 2026
Reiterated: Buy
Price Target: $192
Current: $112.58
Upside: +70.55%
Trevi Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $36
Current: $13.56
Upside: +165.49%
NewAmsterdam Pharma Company
Sep 21, 2026
Reiterated: Buy
Price Target: $58
Current: $20.06
Upside: +189.13%